Kornimate/medical-research-clean huggingface dataset:
therapeutic education of the patients diabetics imprisoned at the paris jail

Conditions: Type 1 or 2 Diabetes

Summary: a lot of data show that therapeutic education is beneficial for diabetic patients. in the french jails, there are very few programs of therapeutic education while this population is usually precarious with no access at care sector before the jail. the purpose of this study is to determinate if the therapeutic education of the diabetic patients is possible in the paris jail "la santé".

the paris jail "la santé" welcomes 600 men who stay 5 month on average. each year, there are between 30 to 40 diabetic patients. in the jail there's a sanitary unit who is a unit of internal medicine of cochin hospital. this unit includes nurses, pharmacists and medical doctors. we propose to include in this study all diabetic patients (type 1 and 2) with the realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic (knowledge of the disease, food, physical activity and care of feet, the therapeutics)

Eligibility criteria:
inclusion criteria: * male patient detained in the mapls of more than 18 years * patient prisoner in the mapls for more than 15 days * patient follow-up for a diabetes of type 1 or type 2 * patient informed about the study and not having opposed to this one * patient taken out of the disciplinary district which had previously been included for this motive exclusion criteria: * patient considered incapable by the investigator to follow an etp program * patient having a bad understanding of the spoken french language * patient whose duration of confinement known about the mapls is strictly lower than 1 month in the inclusion during the year 2013/2014 * patient prisoner in the district of isolation * patient prisoner in the disciplinary district in the inclusion * patient prohibition to communicate with another prisoner already registered on the session to come

Keywords: evolution of the sport, hba1c, imc
validation of new tools for the assessment of cognitive functions and connectivity network in hypertensive patients

Conditions: Hypertension; Cognitive Impairment

Summary: the relationship among hypertension, aging and cognitive decline is complex and not completely understood. purpose of this project will be evaluating early markers of cognitive deterioration in patients with arterial hypertension. in particular, this cross-sectional observational study will be articulated in three phases: 1. neuropsychological evaluation of general cognitive abilities 2. identification and measurement of specific biomarker levels 3. correlation among hypertension, cognitive abilities and biomarkers.


Eligibility criteria:
inclusion criteria: * males or females diagnosed with arterial hypertension between 40 and 65 years of age; * written informed consent prior to enrollment in the study. exclusion criteria: * precedent acute myocardial infarction (ami); * previous stroke and/or transient ischemic attack (tia); * previous or concomitant neurologic or psychiatric pathologies; * neurologic or psychiatric pharmacological therapy.

Keywords: hypertension cognitive impairment biomarkers
intraoral imaging at clinical crown lengthening

Conditions: Dental Caries of Root Surface; Surgery

Summary: crown lengthening surgery is done when a tooth needs to be fixed with a crown. sometimes, not enough of the tooth sticks out above the gum to support a crown. this can happen when a tooth breaks off at the gum line, or when a crown or filling falls out of a tooth and there is decay underneath. to place a crown, the dentist needs to expose more of the tooth. this is done by removing some gum tissue or bone. after surgery, the area will heal in about three months. then, making a crown can begin. this healing period often delays the delivery a final crown. this study is investing a way to make the final impression at the surgery to expedite the delivery of a final crown.

the purpose of this prospective study is to evaluate clinical and radiographic outcomes of single unsplinted fixed restorations made with digital intraoral imaging in conjunction with clinical crown lengthening procedures (clps) compared ones fabricated by the conventional protocol. specific aim 1: to evaluate the clinical outcomes between the experimental group (the digital impression taking at clinical crown lengthening procedures) and the control group (the conventional protocol) hypothesis: there will be no differences in clinical parameters around the teeth between the two groups. approach: the investigators will conduct a prospective clinical study and will compare the changes in gingival recession, the width of keratinized gingiva, and pocket depths around the teeth between the two groups. specific aim 2: to evaluate the radiographic outcome between the experimental group and the control group hypothesis: there will be no difference in crestal bone level around teeth between the two groups. approach: the study will investigate the difference in crestal bone level around the teeth at baseline and 12 months between the two groups.

Eligibility criteria:
inclusion criteria: * age \>18 years * a single-unsplinted crown needed * the tooth must be in the area from the canine to the second molars * a clinical crown lengthening is required to fabricate a crown exclusion criteria: * uncontrolled hypertension * diabetes mellitus * subjects with a history of a long-term use of corticosteroid (\> 6 months) * subjects with a history of taking oral/iv bisphosphonates within the past 2 years * smokers.

Keywords: clinical crown lengthening intraoral imaging emax crown
adding intra-articular dexmedetomidine to levobupivacaine for postoperative analgesia in arthroscopic knee surgery

Conditions: Pain

Summary: the purpose of this study to search efficacy of intra-articular dexmedetomidine addition to levobupivacaine for postoperative analgesia in arthroscopic knee surgery.

patients between 18-65 years and with american society of anesthesiologists' (asa) physical status class i-ii, who were scheduled for arthroscopic knee surgery, were enrolled in a randomised comparative clinical trial. blinding or masking began in the preoperative holding unit. exclusion criteria were psychiatric illness, younger than 18 yo, who has analgesic treatment before the surgery and known hypersensitivity to relevant drugs. all patients received a standard anaesthetic protocol; ecg, heart rate, non-invasive blood pressure, oxygen saturation and temperature were monitored. after preoxygenation, general anaesthesia was induced with sodium pentothal 4 to 7 mg/kg, 1 mcg/kg fentanyl and neuromuscular block was achieved with rocuronium 0.5 mg/kg and trachea was intubated. anesthesia was maintained with desflurane 6% and 50% oxygen in the medical air. randomised patients were achieved dexmedetomidine and levobupivacaine or levobupivacaine intra-articularly 10 minutes before medical tourniquet deaerated. postoperative analgesia was maintained with morphine in patient-controlled analgesia. patients postoperative vas values and analgesic consumptions were recorded in postoperative 24 hours.

Eligibility criteria:
inclusion criteria: * older than 18 yo * scheduled for arthroscopic knee surgery exclusion criteria: * younger than 18 yo * known allergy relevant drugs * contraindication for general anesthesia

Keywords: arthroscopic knee surgery dexmedetomidine analgesia
efficacy and tolerability of baf312 in patients with polymyositis

Conditions: Polymyositis

Summary: this study assessed the efficacy, safety and tolerability of baf312 administered orally in patients with clinically active polymyositis and also in patients with polymyositis who had shown inadequate response to corticosteroids and or dmards (disease modifying antirheumatic drugs).

this study was stopped prematurely due to overall slow recruitment and no evidence for efficacy in a parallel study in dermatomyositis with an assumed similar pathophysiology. with very small sample sizes per group the overall results for this study including primary and all other efficacy and pd data are inconclusive

Eligibility criteria:
inclusion criteria: * "definite" or "probable" for polymyositis at least three months before baseline * active disease as defined by elevated ck levels, or other enzymes, or mri/biopsy if enzymes are normal, and persisting muscle weakness * stable dose of corticosteroid for at least 2 weeks prior to baseline and should not have received a medium or high dose in the last 8 weeks prior to study entry. * patients treated with methotrexate must have been on a stable dose for at least 6 weeks prior to baseline. exclusion criteria: * patients with overlap polymyositis, late-stage polymyositis, or other types of myositis. * preexisting severe cardiac or pulmonary involvement, malignancy of any organ system or significant eye diseases. * uncontrolled diabetes mellitus or diabetes complicated with organ involvement. * pregnant or nursing (lactating) women

Keywords: polymyositis myositis pm chronic muscle inflammation inflammatory myopathy inclusion body myositis
antineoplaston therapy in treating patients with stage iii or stage iv prostate cancer

Conditions: Adenocarcinoma of the Prostate; Stage III Prostate Cancer; Stage IV Prostate Cancer; Recurrent Prostate Cancer

Summary: rationale: antineoplastons are naturally occurring substances that may also be made in the laboratory. antineoplastons may inhibit the growth of cancer cells. purpose: this phase ii trial is studying how well antineoplaston therapy works in treating patients with stage iii or stage iv prostate cancer.

objectives: * determine the antitumor activity of antineoplastons a10 and as2-1 capsules in combination with total androgen blockade in patients with localized, regional or metastatic adenocarcinoma of the prostate by determining the proportion of patients who experience an objective tumor response. * evaluate the adverse effects of and tolerance to this regimen in these patients. outline: this is an open-label study. patients receive gradually escalating doses of antineoplastons a10 and as2-1 capsules orally 6-7 times daily until the maximum tolerated dose is reached. treatment continues for at least 3 months in the absence of disease progression or unacceptable toxicity. concurrently, patients continue hormonal therapy with flutamide, leuprolide, or bicalutamide at the same dose as before beginning antineoplaston therapy. tumors are measured every 4 months for 2 years, every 6 months for 2 years, and then annually for 2 years. projected accrual: a total of 50 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically proven localized, regional, or metastatic adenocarcinoma of the prostate * progressive disease during prior hormonal therapy (both antiandrogen and gonadotropin-releasing hormone) and must continue hormonal therapy * measurable tumors or tumor markers * bone metastases allowed patient characteristics: age: * 18 and over performance status: * karnofsky 60-100% life expectancy: * at least 3 months hematopoietic: * wbc at least 3,000/mm\^3 * platelet count at least 100,000/mm\^3 hepatic: * no hepatic failure * bilirubin no greater than 2.5 mg/dl * sgot no greater than 2 times normal renal: * no chronic renal failure * bun less than 60 mg/dl * creatinine no greater than 2.5 mg/dl or * creatinine clearance greater than 60 ml/min * blood ammonia normal cardiovascular: * no severe heart disease pulmonary: * no severe lung disease other: * fertile patients must use effective contraception during and for 4 weeks after study participation * no serious active infections or fever * no other prior or concurrent second malignancy within the past 2 years prior concurrent therapy: biologic therapy: * at least 4 weeks since prior biologic therapy and recovered chemotherapy: * at least 4 weeks since prior chemotherapy and recovered endocrine therapy: * see disease characteristics radiotherapy: * at least 4 weeks since prior radiotherapy and recovered surgery: * not specified other: * at least 4 weeks since prior investigational clinical trial * no other concurrent treatment for metastatic prostate cancer
pk of levofloxacin in mdr-tb patients

Conditions: Multi-drug Resistant Tuberculosis

Summary: the emergence and spread of multi-drug resistant and extensively-drug resistant strains of mycobacterium tuberculosis (mdr/xdr-tb) have posed a great threat to global tb control and elimination, limiting treatment success rate at worrisome 50% for mdr-tb. among various factors contributing to the development of drug resistance, low drug exposure is well recognized. to overcome this, either new drugs have to be developed or the dose of currently used therapy be optimized, or both. fluoroquinolones (levofloxacin and moxifloxacin) and aminoglycosides are important drugs in the mdr-tb treatment regimen. development of acquired drug resistance to these drugs could complicate and narrow down the available options, and further exacerbate to pre-xdr and xdr-tb. objective: the main objective of this prospective clinical study is to understand the pharmacokinetics of levofloxacin in mdr-tb patients, receiving standard dosage (750-1250mg) based on the body weight and correlate drug exposure, with treatment outcomes. study design: a prospective pharmacokinetic study study population: 20 mdr-tb patients intervention: patients receive once daily oral dosing of levofloxacin (750-1250mg) based on the body weight, under mdr-tb treatment regimen of nepal. main study parameters/end points: the pharmacokinetic parameters(vd, cl, auc etc.) of levofloxacin are the primary end points of the study. the cmax/mic and auc0-24h/mic ratios are the best predictive parameters for efficacy of levofloxacin treatment and will be estimated. pharmacokinetics will be evaluated in plasma and in oral fluid


Eligibility criteria:
inclusion criteria: * patient with tb, with mycobacterium tuberculosis by culture/ gene xpert * patient is 18 years or older with newly diagnosed or previously treated mdr-tb * patient with sputum smear positive for acid-fast bacilli or sputum smear negative but gene xpert (mtb/rif) positive, and resistant to both isoniazid and rifampicin * patients with mdr-tb receiving levofloxacin as a part of mdr-tb regimen exclusion criteria: * patient with neurologic or severe extra-pulmonary manifestations of tuberculosis * pregnant women or breast feeding mothers with mdr-tb * patients with diminished renal functions or on medications for the treatment of renal disorders * body weight \<35 kg * patients treated with aluminium- and magnesium containing antacids and ferrous sulphates, cimetidine and probenecid, theophylline, warfarin, zidovudine, digoxin or cyclosporine.

Keywords: levofloxacin multi-drug resistant tb pharmacokinetics
implementation of the fatty liver index in primary care

Conditions: Hepatic Steatosis; Overweight and Obesity

Summary: this trial aims to evaluate the impact on cardiovascular risk control in individuals in risk of being affected by hepatic steatosis through the implementation of a screening test (fatty liver index) in primary care. medical teams in a primary care center will be divided into 2 groups, with one group using the screening test in their clinical practice. the number of interventions on cardiovascular risk occurring in patients attended by each group of medical teams will be evaluated and compared.


Eligibility criteria:
inclusion criteria: * men and women aged 14 years and older. * attended at the basic care units (bcu) participating in the primary care center baix a mar study. * intention to undergo medical follow-up at the study center. * body mass index ≥ 25. exclusion criteria: * pregnant women * alcohol consumption habit (standard drink unit (sdu); one sdu equals 10 grams of alcohol. risky consumption is considered from 4 sdus in men and 2 sdus in women). * displaced patients not assigned to the study center. * patients classified as advanced chronic care model or complex chronic patient. * participants diagnosed with any of the following pathologies: chronic liver diseases, including hepatic steatosis; dementia; active oncological diseases * cognitive or affective pathology that limits the ability to collaborate with lifestyle interventions carried out at the center. * patients under the care of endocrinology specialists. * participation in another clinical trial involving an experimental intervention during the period of this trial.
effects of resistance-band training and creatine and whey protein

Conditions: Sarcopenia in Elderly

Summary: the primary purpose of this research is to compare the effects of creatine monohydrate and/or whey protein supplementation during the first 10 weeks of a 20-week resistance-band training program on measures of body composition (whole-body lean tissue mass, total body water), arm and leg muscle thickness, upper- and lower-body muscle performance (i.e., strength, endurance) and functional ability (walking speed, balance). a secondary purpose of this research is to examine the effects of supplementation cessation (i.e., no creatine and/or whey protein supplementation) during the final 10 weeks of the 20-week resistance-band training program on these measures.

sarcopenia, characterized by the age-related reduction in strength, muscle mass, and physical function, decreases the ability to perform activities of daily living. physical inactivity and inadequate nutrition are contributing factors to the development of sarcopenia. resistance training is a safe, viable and effective intervention which increases measures of muscle and bone mass, muscle performance (i.e., strength, endurance) and functional ability in older adults. however, older adults indicate that high costs and difficulty finding training programming and/or facilities are barriers to participating in resistance training. home-based resistance-band training is safe, effective and serves as a viable alternative to traditional resistance training (i.e., involving free-weights and machine-based equipment). from a healthy aging perspective, resistance-band training elicits similar improvements in strength (primary indicator of sarcopenia) and functional ability compared to traditional resistance training in older adults. in addition to resistance training (involving resistance-bands), creatine and whey protein supplementations have also been shown to have favorable effects on measures of muscle, bone and functional ability in older adults. however, no study has examined the effects of resistance-band training and creatine and whey protein supplementation in older adults.

Eligibility criteria:
inclusion criteria: * untrained (defined as those performing ≤ 1 resistance training session per week for ≥ 6 weeks prior to the start of the study) exclusion criteria: * taking creatine monohydrate within 30 days prior to the start of the study * currently ingesting whey protein * have pre-existing allergies to latex, fruit, dairy, nuts, seafood and mustard

Keywords: resistance exercise creatine whey protein strength lean mass
metformin treatment in polycystic ovary syndrome (pcos)

Conditions: Polycystic Ovary Syndrome

Summary: pcos occurs when a woman does not release an egg regularly each month, causing her periods to be irregular. women with pcos can also have increased hair growth on the face and body, acne, head balding, infertility, pre-diabetes, and diabetes. pcos is commonly treated with oral contraceptive pills (also known as the birth control pills). sometimes, a medication called metformin is also used to treat pcos, especially if a woman has evidence of insulin resistance or if fertility is desired. unfortunately, metformin works in only some women with pcos. the mechanism through which metformin works in pcos is not clear and it difficult to predict who will benefit from metformin treatment and who will not. the investigators are doing this research study to look at how the medication metformin affects the cells in the body of patients with pcos. specifically, the investigators will look at how metformin affects the mitochondria. mitochondria are the part of cells that produce fuel (energy) for other cells and play a role in metabolism. the investigators would like to see whether there is a relationship between mitochondrial activity and symptoms of polycystic ovary syndrome (pcos) before and after treatment with metformin. they would also like to study whether genes affect the response to metformin in women with pcos.

women who are eligible to enroll in this study will be treated with the medication metformin for 12 weeks. before and after treatment with metformin, the following will be assessed: * weight, blood pressure, waist circumference * lipids (cholesterol) * hormone levels (including testosterone and other androgens) * iv glucose tolerance test (to assess for early evidence of insulin resistance) * effect of metformin on muscle mitochondria (this will involve one mri scan and one muscle biopsy each before and after treatment with metformin) ovulation will be closely monitored at least twice a month with pelvic ultrasounds and blood tests for estrogen and progesterone levels.

Eligibility criteria:
inclusion criteria: * polycystic ovary syndrome * no hormonal or antidiabetic medications for 1 month * good general health exclusion criteria: * smoker * acute infection or chronic disease * diabetes * pregnant or trying to get pregnant over next half year * bleeding disorders * any metal or foreign implants (e.g., aneurysm clips, ear implants, heart pacemakers or defibrillators)

Keywords: polycystic ovary syndrome pcos acne infertility irregular menses irregular period mitochondria metabolism
prognostic biomarkers in tumor tissue samples from young patients with neuroblastoma

Conditions: Disseminated Neuroblastoma; Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Stage 4S Neuroblastoma

Summary: this research study is studying biomarkers in tumor tissue samples from young patients with neuroblastoma. studying samples of tissue from patients with cancer in the laboratory may help doctors identify biomarkers and learn more about biomarkers related to cancer

primary objectives: i. determine whether ubiquitin carboxyl-terminal hydrolase 1 (uchl1) expression is an indirect cancer stem cell marker in pediatric patients with neuroblastoma. correlate uchl1 expression with staging information and patient's outcome. study subtype: observational observational study model: case-control time perspective: retrospective biospecimen retention: none retained biospecimen description: tissue study population description: tissue microarray samples from patients with neuroblastoma supplied by the cog biopathology center sampling method: probability outline: archived tissue microarray samples are analyzed for ubiquitin carboxyl-terminal hydrolase 1 (uchl1) expression by uchl1 monoclonal antibody and peroxidase technique. results are then compared with patients' clinical data, including age at diagnosis, race, date of diagnosis, histology, stage and location at diagnosis, presence of cancer predisposition, date of completion of treatment, surgery performed, type of chemotherapy received, history of recurrence, and status (alive with disease, alive without disease, dead), if available.

Eligibility criteria:
inclusion criteria: * diagnosed with neuroblastoma * tissue microarrays containing normal and neuroblastoma samples provided by the children's oncology group (cog) biopathology center